In recent years, synthetic lethality has been recognized as a solid paradigm for anticancer
therapies. The discovery of a growing number of synthetic lethal targets has led to a …

Many clinical decisions in oncology practice rely on the presence or absence of an alteration
in a single genetic locus, be it a pathogenic variant in a hereditary cancer gene or activating …

Simple Summary A characteristic across several cancer types is a homologous
recombination deficiency (HRD). HRD is associated with a better response to several …

Ovarian carcinoma (OC) still represents an insidious and fatal malignancy, and few
significant results have been obtained in the last two decades to improve patient survival …

Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the
management of epithelial ovarian cancer. The concept of 'synthetic lethality'is exploited by …

Background Due to the abundant usage of chemotherapy in young triple-negative breast
cancer (TNBC) patients, the unbiased prognostic value of BRCA1-related biomarkers in this …

Importance Testing for homologous recombination deficiency is required for the optimal
treatment of high-grade epithelial ovarian cancer. The search for accurate biomarkers is …

For many individuals harboring a variant of uncertain functional significance (VUS) in a
homologous recombination (HR) gene, their risk of developing breast and ovarian cancer is …

Purpose BRCA-deficient breast cancers (BC) are highly sensitive to platinum-based
chemotherapy and PARP inhibitors due to their deficiency in the homologous recombination …

PURPOSE To meet the urgent need for accessible homologous recombination-deficient
(HRD) test options, we validated a laboratory-developed test (LDT) and a functional RAD51 …